<http://webisa.webdatacommons.org/284424135>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/339102636>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/284424135> .
<http://webisa.webdatacommons.org/prov/424431648>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/284424135> .
<http://webisa.webdatacommons.org/284424135>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<nih.gov> .
<http://webisa.webdatacommons.org/284424135>	<http://www.w3.org/ns/prov#value>	"Stroke, myocardial infarction, inflammatory syndromes, infectious and parasitic diseases, autoimmune disorders, cancer, and aging are but some examples of conditions in which Hsps and molecular chaperones are being scrutinized." .